Speakers - Sachs Associates
Speakers - Sachs Associates
Speakers - Sachs Associates
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
CONTACT<br />
Barbara Stiefel<br />
Office Management<br />
ADDRESS<br />
Wagistrasse 27<br />
CH-8952 Schlieren<br />
Switzerland<br />
TELEPHONE<br />
+41 44 730 51 80<br />
Barbara Stiefel<br />
+41 44 730 51 80<br />
FAX<br />
+41 44 730 51 81<br />
EMAIL<br />
info@delenex.com<br />
YEAR FOUNDED<br />
2009<br />
Delenex Therapeutics AG<br />
www.delenex.com<br />
FINANCIAL SUMMARY<br />
Series A (CHF 30.2 Mio) closed May 2011.<br />
COMPANY PROFILE<br />
Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibodies for<br />
(i) topical administration in severe chronic conditions, and<br />
(ii) systemic administration in acute diseases.<br />
Its proprietary compound class, PENTRA® antibodies, are highly tissue-penetrant.<br />
The company is focused in immuno-inflammation, and within this in three specific areas: dermatology, GI and<br />
acute inflammation.<br />
Three PoC clinical projects are currently active<br />
1. antibody-containing ointment for topical administration in plaque psoriasis<br />
2. antibody-containing gel for topical administration in Crohn’s fistulas (entry indication for IBD)<br />
3. intravenous administration for Behçet’s Disease (entry indication for acute inflammation)<br />
Two clinical trials have already met their endpoints<br />
a. Proof of mechanism in psoriasis patients (safety and exploratory efficacy)<br />
b. Systemic safety in healthy volunteers<br />
MANAGEMENT<br />
Eric de La Fortelle, Chief Executive Officer<br />
Thomas Jung, Chief Medical Officer<br />
Titus Kretzschmar, Chief Scientific Officer<br />
Jakob Schlapbach, Chief Financial Officer<br />
t back :: next u<br />
WELCOME PHARMA LICENSING GROUPS<br />
SPEAKERS<br />
PRESENTING COMPANIES SUPPORTING ORGANISATIONS<br />
ORGANISERS
Change language